CytomX Therapeutics, Inc. (CTMX)

CTMX rose 2.2% while peers showed mixed moves: ADCT up 2.53%, LRMR and TECX up 5.37% each, but AUTL and IMAB down 1.22% and 1.49%. This pattern suggests stock-specific factors rather than a uniform biotech move. ... News-driven moves mostly align with the nature of announcements, with offerings draw…

Stocks are volatile financial instruments. Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnie…

On May 19, 2026, Wolfe Research initiated coverage of CytomX Therapeutics, Inc. (NASDAQ:CTMX) with an Outperform rating and a $6 price target.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. NasdaqGS:CTMX Earnings and Revenue Growth May 11th 2026

Varseta-M Phase I Data -- Confirmed overall response rate (ORR) between 20% and 32%, and approximately 7 months median progression-free survival (PFS) in late line metastatic colorectal cancer, based on March 2026 update. Enrollment Milestone -- Dose optimization cohorts completed enrollment ...